Skip to main content
SpringerLink
Log in

Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The urgent need to treat type 2 diabetes mellitus (T2DM), which is currently reaching epidemic proportions, has been a major focus of healthcare systems and policy makers worldwide. Pharmacological treatment and lifestyle interventions together with the control of cardiovascular risk factors are the main strategies to prevent or delay the onset of T2DM. The present review discusses the state of the art knowledge of effective therapeutic approaches (metformin, thiazolidinediones, nateglinides, α-glucosidase inhibitors, incretin-based and angiotensin-based therapies, weight reducers, statins, fibric acid derivatives), including surgery, and identifies the major lifestyle changes for specific target groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ariza MA, Vimalananda VG, Rosenzweig JL (2010) The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocr Metab Disord 11(1):1–10. doi:10.1007/s11154-010-9128-2

    Article  PubMed  Google Scholar 

  2. Fonseca VA, Smith H, Kuhadiya N, Leger SM, Yau CL, Reynolds K, Shi L, McDuffie RH, Thethi T, John-Kalarickal J (2009) Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care 32(9):1632–1638. doi:10.2337/dc09-0670

    Article  PubMed  Google Scholar 

  3. WHO (2008) Diabetes fact sheet. http://www.who.int/mediacentre/factsheets/fs312/en/. July 30, 2010

  4. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053

    Article  PubMed  Google Scholar 

  5. McFarlane SI, Shin JJ, Rundek T, Bigger JT (2003) Prevention of type 2 diabetes. Curr Diab Rep 3(3):235–241

    Article  PubMed  Google Scholar 

  6. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289(1):76–79. doi:10.1001/jama.289.1.76

    Article  PubMed  Google Scholar 

  7. Grant SJ, Bensoussan A, Chang D, Kiat H, Klupp NL, Liu JP, Li X (2009) Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 4:CD006690. doi:10.1002/14651858.CD006690.pub2

  8. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, Grobbee DE, Batty D, Woodward M (2009) Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med 169(22):2053–2063. doi:10.1001/archinternmed.2009.439

    Article  PubMed  Google Scholar 

  9. Baliunas DO, Taylor BJ, Irving H, Roerecke M, Patra J, Mohapatra S, Rehm J (2009) Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 32(11):2123–2132. doi:10.2337/dc09-0227

    Article  PubMed  CAS  Google Scholar 

  10. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J (2005) Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2:CD005270 doi:10.1002/14651858.CD005270

  11. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343–1350

    Article  PubMed  CAS  Google Scholar 

  12. American Diabetes Association, National Institute of Diabetes, Digestive and Kidney Diseases (2002) The prevention or delay of type 2 diabetes. Diabetes Care 25(4):742–749

    Google Scholar 

  13. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368(9548):1673–1679. doi:10.1016/S0140-6736(06)69701-8

    Article  PubMed  Google Scholar 

  14. [No authors listed] (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22 (4): 623–634

    Google Scholar 

  15. [No authors listed] (2000) The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care 23 (11): 1619–1629

    Google Scholar 

  16. Farag A, Karam J, Nicasio J, McFarlane SI (2007) Prevention of type 2 diabetes: an update. Curr Diab Rep 7(3):200–207

    Article  PubMed  CAS  Google Scholar 

  17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403. doi:10.1056/NEJMoa012512

    Article  PubMed  CAS  Google Scholar 

  18. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J (2006) Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29(9):2102–2107. doi:10.2337/dc06-0560

    Article  PubMed  Google Scholar 

  19. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4):537–544

    Article  PubMed  CAS  Google Scholar 

  20. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM (2008) The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 4(7):382–393. doi:10.1038/ncpendmet0843

    Article  PubMed  Google Scholar 

  21. Bosi E (2009) Metformin—the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 11(Suppl 2):3–8. doi:10.1111/j.1463-1326.2008.01031.x

    Article  PubMed  CAS  Google Scholar 

  22. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ (2010) Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 376(9735):103–111. doi:10.1016/S0140-6736(10)60746-5

    Article  PubMed  CAS  Google Scholar 

  23. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA (2009) Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 35(5):385–391. doi:10.1016/j.diabet.2009.03.005

    Article  PubMed  CAS  Google Scholar 

  24. Kalaitzidis RG, Sarafidis PA, Bakris GL (2009) Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 15(5):529–536

    Article  PubMed  CAS  Google Scholar 

  25. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51(9):2796–2803

    Article  PubMed  CAS  Google Scholar 

  26. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54(4):1150–1156. doi:10.2337/diabetes.54.4.1150

    Article  PubMed  Google Scholar 

  27. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096–1105. doi:10.1016/S0140-6736(06)69420-8

    Article  PubMed  CAS  Google Scholar 

  28. Defronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner R, Reaven PD, Schwenke D, Stentz FB, Tripathy D (2009) Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord 9:17. doi:10.1186/1472-6823-9-17

    Article  PubMed  Google Scholar 

  29. Durbin RJ (2004) Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6(4):280–285. doi:10.1111/j.1462-8902.2004.0348.x DOM348

    Article  PubMed  CAS  Google Scholar 

  30. Sato Y, Nishikawa M, Shinkai H, Sukegawa E (1991) Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res Clin Pract 12(1):53–59

    Article  PubMed  CAS  Google Scholar 

  31. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR (2008) Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 156(4):623–632

    Article  PubMed  Google Scholar 

  32. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, De Grauw WJ (2006) Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst Rev 4:CD005061 doi:10.1002/14651858.CD005061.pub2

  33. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072–2077. doi:10.1016/S0140-6736(02)08905-5

    Article  PubMed  CAS  Google Scholar 

  34. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K (2009) Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 18(10):1495–1503. doi:10.1517/14728220903241633

    Article  PubMed  CAS  Google Scholar 

  35. Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA (2008) Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31(1):30–35

    Article  PubMed  CAS  Google Scholar 

  36. Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31(1):108–113

    Article  PubMed  CAS  Google Scholar 

  37. Brandou F, Brun JF, Mercier J (2005) Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. J Clin Endocrinol Metab 90(2):761–767. doi:10.1210/jc.2004-0329

    Article  PubMed  CAS  Google Scholar 

  38. Rossner SM, Neovius M, Mattsson A, Marcus C, Norgren S (2010) HOMA-IR and QUICKI: decide on a general standard instead of making further comparisons. Acta Paediatr 99(11):1735–1740. doi:10.1111/j.1651-2227.2010.01911.x APA1911

    Article  PubMed  Google Scholar 

  39. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B (2001) Ramipril and the development of diabetes. JAMA 286(15):1882–1885. doi:10.1001/jama.286.15.1882

    Article  PubMed  CAS  Google Scholar 

  40. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353(9153):611–616. doi:10.1016/S0140-6736(98)05012-0

    Article  PubMed  CAS  Google Scholar 

  41. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23): 2981–2997

  42. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311):1004–1010

    Article  PubMed  CAS  Google Scholar 

  43. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355(15):1551–1562

    Article  PubMed  Google Scholar 

  44. McFarlane SI (2009) Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev Cardiovasc Ther 7(11):1363–1371. doi:10.1586/erc.09.115

    Article  PubMed  CAS  Google Scholar 

  45. McFarlane SI, Kumar A, Sowers JR (2003) Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91(12A):30H–37H. doi:10.1016/S0002-9149(03)00432-6

    Article  PubMed  CAS  Google Scholar 

  46. Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41(2):127–133

    Article  PubMed  CAS  Google Scholar 

  47. Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64(22):2537–2565. doi:10.1016/S1262-3636(07)70147-7

    Article  PubMed  CAS  Google Scholar 

  48. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155–161

    Article  PubMed  CAS  Google Scholar 

  49. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjostrom L (2000) Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160(9):1321–1326

    Article  PubMed  CAS  Google Scholar 

  50. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735–742

    Article  PubMed  CAS  Google Scholar 

  51. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375(9726):1634–1639

    Article  PubMed  CAS  Google Scholar 

  52. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3):357–362

    PubMed  CAS  Google Scholar 

  53. Tenenbaum A, Motro M, Fisman EZ (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4:14

    Article  PubMed  Google Scholar 

  54. Rovellini A, Sommariva D, Branchi A, Maraffi F, Montalto C, Gandini R, Fasoli A (1992) Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res 25(3):237–245

    Article  PubMed  CAS  Google Scholar 

  55. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S (2005) Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 26(19):2032–2038

    Article  PubMed  CAS  Google Scholar 

  56. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S (2004) Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109(18):2197–2202

    Article  PubMed  CAS  Google Scholar 

  57. Long SD, O'Brien K, MacDonald KG Jr, Leggett-Frazier N, Swanson MS, Pories WJ, Caro JF (1994) Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 17(5):372–375

    Article  PubMed  CAS  Google Scholar 

  58. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222(3):339–350, discussion 350–332

    Article  PubMed  CAS  Google Scholar 

  59. Pories WJ, MacDonald KG Jr, Flickinger EG, Dohm GL, Sinha MK, Barakat HA, May HJ, Khazanie P, Swanson MS, Morgan E et al (1992) Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 215(6):633–642, discussion 643

    Article  PubMed  CAS  Google Scholar 

  60. Pories WJ, MacDonald KG Jr, Morgan EJ, Sinha MK, Dohm GL, Swanson MS, Barakat HA, Khazanie PG, Leggett-Frazier N, Long SD et al (1992) Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 55(2 Suppl):582S–585S

    PubMed  CAS  Google Scholar 

  61. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683–2693

    Article  PubMed  Google Scholar 

  62. Dixon AF, Dixon JB, O'Brien PE (2005) Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90(2):813–819

    Article  PubMed  CAS  Google Scholar 

  63. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299(3):316–323

    Article  PubMed  CAS  Google Scholar 

  64. Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, Ferrannini E (2006) Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49(9):2136–2143. doi:10.1007/s00125-006-0337-x

    Article  PubMed  CAS  Google Scholar 

  65. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240(2):236–242. doi:10.1097/01.sla.0000133117.12646.48

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Hospital de São João, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal

    Selma B. Souto & Daniel C. Braga

  2. Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal

    Selma B. Souto, Daniel C. Braga & José L. Medina

  3. Institute of Biotechnology and Bioengineering, Centre of Genomics and Biotechnology, University of Trás-os-Montes and Alto Douro (CGB-UTAD/IBB), P.O. Box 1013, P-5001-801, Vila Real, Portugal

    Eliana B. Souto

  4. Faculty of Health Sciences, Fernando Pessoa University, Rua Carlos da Maia, 296, P-4200-150, Porto, Portugal

    Eliana B. Souto

Authors
  1. Selma B. Souto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eliana B. Souto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel C. Braga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José L. Medina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Selma B. Souto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Souto, S.B., Souto, E.B., Braga, D.C. et al. Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). Eur J Clin Pharmacol 67, 653–661 (2011). https://doi.org/10.1007/s00228-011-1038-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-011-1038-z

Keywords

Search

Navigation